Decision Resources, Inc., announces the publication of Type 2 Diabetes, a new study that evaluates the commercial potential of novel agents to treat this indication. We believe that over the course of our 2000-2010 study period, drug companies will leverage rapid advances in research on the etiology and molecular basis of type 2 diabetes to uncover further novel drug targets. This study offers critical strategic analysis to help companies competing in this market to position their products.

  (Photo: )    GLP-1 Agonists Poised for Success 

Thought leaders interviewed for this study are most enthusiastic about glucagon-like peptide-1 (GLP-1) agonists, under development by Amylin Pharmaceuticals, Novo Nordisk, and Novartis. This class of drugs exhibits multiple physiological benefits, including induction of insulin secretion in the presence of elevated glucose levels, delay of gastric emptying, and reduction of hepatic glucose output. Achieving this range of benefits now requires several different classes of drugs, and a new compound that would reduce polypharmacy among diabetics would be welcome.

Inhalable Insulin Will Capture Market Share

The three major producers of insulin-Eli Lilly, Novo Nordisk, and Aventis (with Pfizer)-are all developing inhalable formulations of insulin with small company partners. Exubera, the dry powder insulin formulation developed by Inhale Therapeutic Systems in partnership with Pfizer and Aventis is expected to be the first to market. Aradigm's AERx inhaled insulin technology (in collaboration with Novo Nordisk), Dura Pharmaceuticals' (recently purchased by Elan) Spiros inhaler (in collaboration with Eli Lilly), and AeroGen's AeroDose Inhaler, which uses the company's proprietary aerosol generator technology, each offer unique advantages. Thought leaders believe that the convenience of inhalable insulin will lead to better patient compliance, although inhalable insulin not expected to replace injected insulin in the near future.

Thiazolidinediones Move Forward

Thought leaders we interviewed believe that the thiazolidinediones will play an increasingly important role in the treatment of type 2 diabetes. In addition, this drug class could potentially become first-line agents if future clinical data continue to support preliminary findings suggesting that thiazolidinediones may halt, and even possibly repair, pancreatic beta-cell damage.

Type 2 Diabetes offers invaluable market intelligence for companies developing therapies to treat this indication. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or


NewsCom: AP Archive: PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,